ProQR Therapeutics

Yahoo Finance • 2 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featu... Full story

Yahoo Finance • 3 months ago

ProQR Therapeutics' SWOT analysis: RNA editing pioneer's stock faces clinical hurdles

ProQR Therapeutics N.V. (NASDAQ:PRQR), a biotechnology company specializing in RNA editing technology, is making significant strides in its clinical development pipeline. The company’s innovative Axiomer platform has garnered attention fro... Full story

Yahoo Finance • 3 months ago

ProQR stock advances as JMP reiterates bullish stance on RNA editing

Investing.com - ProQR Therapeutics N.V. (NASDAQ:PRQR) stock rose Tuesday, extending its impressive 11.92% gain over the past week, after JMP Securities reiterated its Market Outperform rating and $8.00 price target on the RNA editing compa... Full story

Yahoo Finance • 3 months ago

ProQR submits clinical trial application for RNA editing therapy

LEIDEN/CAMBRIDGE - ProQR Therapeutics NV (NASDAQ:PRQR), a $228.59 million market cap biotechnology company that has seen an 11.34% gain in the past week, has submitted a Clinical Trial Application to the European Medicines Agency for its l... Full story

Yahoo Finance • 3 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing Pro... Full story

Yahoo Finance • 7 months ago

ProQR Announces Year End 2024 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in... Full story

Yahoo Finance • 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position... Full story

Yahoo Finance • 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strength... Full story

Yahoo Finance • 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA ed... Full story

Yahoo Finance • 2 years ago

ProQR Therapeutics Provides Update on Ophthalmic Assets

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previ... Full story

Yahoo Finance • 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA edi... Full story

Yahoo Finance • 2 years ago

ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability

We feel now is a pretty good time to analyse ProQR Therapeutics N.V.'s (NASDAQ:PRQR) business as it appears the company may be on the cusp of a considerable accomplishment. ProQR Therapeutics N.V., a biotechnology company, focuses on the d... Full story

Yahoo Finance • 2 years ago

ProQR Announces First Quarter 2023 Operating and Financial Results

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic are... Full story

Yahoo Finance • 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA edi... Full story

Yahoo Finance • 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA ed... Full story

Yahoo Finance • 3 years ago

Why Shares of ProQR Therapeutics Dropped on Wednesday

Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-... Full story

Yahoo Finance • 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025Axiomer activity demonstrated acros... Full story

Yahoo Finance • 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully de... Full story

Yahoo Finance • 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations... Full story

Yahoo Finance • 3 years ago

ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will h... Full story